All lobbying filings

THE MCMANUS GROUP

Lobbying for GILEAD SCIENCES, INC. · Client is a biopharmaceutical company that develops medicines in areas of unmet need.

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$60,000.00

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

S 832
EPIC Act of 2025
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…

Lobbying activity 2

Health Issues

Issues related to reforming and increasing transparency within the 340B Drug Pricing Program. Issues related to federal funding for HIV prevention.

Medicare/Medicaid

Support for EPIC Act - S. 832, and H.R. 1492, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.